Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.2% - Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares fell 5.2% during mid-day trading on Tuesday . The stock traded as low as $17.53 and last traded at $17.47. 146,819 shares were traded during mid-day trading, a decline of 46% from the average session volume of 273,303 shares. The stock had previously closed at $18.42.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of recent research reports. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, Robert W. Baird cut their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Stock Performance

The company has a market cap of $560.23 million, a P/E ratio of -6.97 and a beta of 1.48. The firm has a 50 day moving average price of $18.95 and a 200-day moving average price of $21.45.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently bought and sold shares of DNTH. Octagon Capital Advisors LP boosted its holdings in Dianthus Therapeutics by 11.0% in the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock worth $42,478,000 after buying an additional 231,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after purchasing an additional 618 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of Dianthus Therapeutics by 5.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 189,000 shares of the company's stock worth $3,428,000 after buying an additional 9,000 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in Dianthus Therapeutics by 3.4% during the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock valued at $332,000 after purchasing an additional 602 shares during the period. Finally, Vestal Point Capital LP increased its stake in shares of Dianthus Therapeutics by 58.1% in the first quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company's stock worth $30,839,000 after purchasing an additional 625,069 shares in the last quarter. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.